The STOP ICH trial is a multicenter, prospective, randomized, open-label, blinded end-point (PROBE) study designed to assess the efficacy and safety of atorvastatin in patients with intracerebral hemorrhage (ICH) presenting within 3 to 24 hours of symptom onset.
Patients with a diagnosis of spontaneous intracerebral hemorrhage (ICH) confirmed by computed tomography (CT);
Age 18-80 years;
Hematoma located in the supratentorial region;
Time from symptom onset or last known well to baseline CT ranging from 3 to 24 hours;
ICH secondary to trauma, tumor, aneurysm, arteriovenous malformation (AVM), vascular anomaly, hemorrhagic transformation of infarction, cerebral venous thrombosis, or anticoagulant-related ICH;
Patients who have undergone or are scheduled for immediate surgical intervention;
Pregnancy or lactation;
Use of oral anticoagulants within 1 month prior to symptom onset;